Literature DB >> 3125399

Effect of human growth hormone-releasing hormone on GH secretion in Cushing's syndrome and non-endocrine disease patients treated with glucocorticoids.

M Hotta1, T Shibasaki, A Masuda, T Imaki, N Sugino, H Demura, N Ling, K Shizume.   

Abstract

The GH response to 100 micrograms human growth hormone-releasing hormone (hGRH) given intravenously was evaluated in eleven patients with Cushing's syndrome who had been ill for more than one year and in six patients with non-endocrine diseases who were treated with glucocorticoid for one to twelve weeks. Extremely low to no response of plasma GH to hGRH injection was noted in all seven patients with Cushing's disease and in four patients with Cushing's syndrome due to an adrenal adenoma or carcinoma. In contrast, all six patients with non-endocrine diseases who were treated with glucocorticoid showed normal GH responses to hGRH. These results suggest that the diminished hGRH-induced GH secretion in patients with Cushing's syndrome might be caused by the prolonged period of hypercortisolemia.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3125399     DOI: 10.1016/0024-3205(88)90427-4

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

1.  Decreased GH secretion and enhanced ACTH and cortisol release after ghrelin administration in Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH.

Authors:  Silvia Regina Correa-Silva; Sérgio Oliva Nascif; Ana-Maria Judith Lengyel
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

2.  IGF-I levels rise and GH responses to GHRH decrease during long-term prednisone treatment in man.

Authors:  M H Borges; A C Pinto; F B DiNinno; C Camacho-Hübner; A Grossman; C E Kater; A M Lengyel
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

Review 3.  Psychiatric implications of altered limbic-hypothalamic-pituitary-adrenocortical activity.

Authors:  F Holsboer
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.